ReviewThe Journal of clinical and aesthetic dermatology2017
Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.
Review in The Journal of clinical and aesthetic dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Comparison of the Effectiveness of Ivermectin 1% Cream and Ketoconazole 2% Cream in Treating Facial Seborrheic Dermatitis: A Double-Blind, Randomized, Controlled Clinical Trial.Health science reports · 2026Article
- Pustular rosacea secondary toJAAD case reports · 2023Article
- Demodicosis in Different Age Groups and Alternative Treatment Options-A Review.Journal of clinical medicine · 2023Review
- The Importance of Assessing Burning and Stinging when Managing Rosacea: A Review.Acta dermato-venereologica · 2021Review
- Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS).The Journal of clinical and aesthetic dermatology · 2020Article
- Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS).The Journal of clinical and aesthetic dermatology · 2019Article
- Consensus on the therapeutic management of rosacea - Brazilian Society of Dermatology.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently, the potential modes of action of topical ivermectin in rosacea have been speculated but not studied. Short-term studies (12 week), long-term studies (up to 52 weeks), and case report series have now been completed, and topical ivermectin (IVM), formulated as a 1% cream that is applied once daily, has been shown to be effective, well-tolerated, and safe for the treatment of rosacea. This article reviews outcomes from studies that support dual modes of action, including both anti-inflammatory and anti-parasitic effects.
Indexed as
Identifiers
29515751PMC5749619W2993294610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.